Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
CD2-H82E8 | Human | Biotinylated Human CD52 Protein, His,Avitag™ |
|
||
CD2-H525a | Human | Human CD52 Protein, Fc Tag |
|
||
CD2-H82F3 | Human | Biotinylated Human CD52 Protein, Fc,Avitag™ |
|
Anti-Human CD52 MAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) with an affinity constant of 71.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Alemtuzumab | LDP-03; GZ-402673 | Approved | Genzyme Corp, Bayer AG | Campath, Lemtrada, MabCampath | United States | Multiple Sclerosis | Genzyme Corp | 2001-05-07 | Myositis, Inclusion Body; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Lymphoproliferative Disorders; Peritoneal Neoplasms; Sezary Syndrome; Pancytopenia; Lymphoma, T-Cell, Peripheral; Multiple Sclerosis; Rejection of organ transplantation; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Hodgkin Disease; Graft vs Host Disease; Kidney Diseases; Rejection of renal transplantation; Hematologic Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1; Bone marrow transplant rejection; Leukemia; Multiple Sclerosis, Relapsing-Remitting | Details |
Alemtuzumab | LDP-03; GZ-402673 | Approved | Genzyme Corp, Bayer AG | Campath, Lemtrada, MabCampath | United States | Multiple Sclerosis | Genzyme Corp | 2001-05-07 | Myositis, Inclusion Body; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Lymphoma; Leukemia, Prolymphocytic, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell; Lymphoproliferative Disorders; Peritoneal Neoplasms; Sezary Syndrome; Pancytopenia; Lymphoma, T-Cell, Peripheral; Multiple Sclerosis; Rejection of organ transplantation; Leukemia-Lymphoma, Adult T-Cell; Myelodysplastic Syndromes; Hodgkin Disease; Graft vs Host Disease; Kidney Diseases; Rejection of renal transplantation; Hematologic Neoplasms; Ovarian Neoplasms; Diabetes Mellitus, Type 1; Bone marrow transplant rejection; Leukemia; Multiple Sclerosis, Relapsing-Remitting | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase 2 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
ALLO-647 | ALLO-647 | Phase 2 Clinical | Allogene Therapeutics Inc | Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) | Phase 1 Clinical | Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd | Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details | |
Alemtuzumab biosimilar(BioXpress) | BX-1523; BXT-1523 | Clinical | Bioxpress Therapeutics Sa | Multiple Sclerosis; Leukemia, B-Cell | Details |
Alemtuzumab biosimilar (Zhangjiang Biotechnology) | Phase 2 Clinical | Shanghai Zhangjiang Biotechnology Co Ltd | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
ALLO-647 | ALLO-647 | Phase 2 Clinical | Allogene Therapeutics Inc | Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) | Phase 1 Clinical | Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd | Leukemia, B-Cell; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details | |
Alemtuzumab biosimilar(BioXpress) | BX-1523; BXT-1523 | Clinical | Bioxpress Therapeutics Sa | Multiple Sclerosis; Leukemia, B-Cell | Details |
This web search service is supported by Google Inc.